Edwards-backed CardioKinetix reports China heart failure data; U.S. pivotal results expected in 2016
Startup CardioKinetix has reported positive pivotal data from China on its catheter-based heart failure treatment, the Parachute Ventricular Partitioning Device. It expects these study results to support a regulatory submission with the China Food and Drug Administration.
China's FDA has disclosed its first approval of proton carbon ion therapy equipment by clearing the Siemens device at the Shanghai Heavy Ion Proton Hospital to treat cancer patients with radiation.
India's government has threatened to place restrictions on imports of nonessential items, including pharmaceuticals, from China if it does not ease some of its "protectionist tendencies" toward India products.
ZAI Lab of Shanghai has in-licensed from Bristol-Myers Squibb China rights to the Phase III liver cancer drug brivanib, an oral kinase inhibitor for oncology indications including hepatocellular carcinoma.
Eli Lilly & Co. and China's Innovent Biologics agreed to co-develop at least three experimental cancer drugs--including one from Lilly's research labs and two from Innovent--in a deal that will see the Indianapolis-based company pay $56 million upfront.
Here's a side effect to the series of quality scares about China-made products. Chinese tourists to Japan took advantage of the recent weeklong Lunar New Year holiday to stock up on over-the-counter remedies and novel therapies they can't buy at home.
Chinese tourists to Japan took advantage of the recent week-long Lunar New Year holiday to stock up on over-the-counter remedies and novel therapies unavailable at home, according to Japanese social media analytics company Hottolink.
China's Sinovac Biotech said it is close to receiving marketing approval for its vaccine for preventing the EV71 virus responsible for hand, foot and mouth disease, a common ailment in Asia that often is fatal.
Beijing and New Delhi plan ministerial-level trade discussions to tackle pharmaceutical and four other major issues involving services and products that India can supply to China, according to an India official.
South Korean bio pharma Green Cross will build a cell therapy manufacturing center in China's Guizhou province to distribute products in China.